EUVIMEDEUVIMED entdecken
Crossref

Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3

Junwen Zhu, Ying Lu, Qingyuan Zhang

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Junwen Zhu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province 150081, China. Hauptthemen laut MEDLINE: MicroRNAs, Exosomes, Trastuzumab, Breast Neoplasms. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab is frequently utilized to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer, though its effectiveness is frequently hindered by the development of chemotherapy resistance. Recent research has indicated that exosomes, serving as carriers for genetic material exchanged among diverse tumor cell populations, contribute to the transmission of drug resistance, thereby promoting cancer progression. However, the exact mechanisms through which exosomes originating from breast cancer influence drug resistance remain unclear. In this study, we performed sequencing on exosomes both before and after trastuzumab treatment. Our results demonstrated a significant reduction in miR-3529-3p levels in exosomes from breast cancer patients following trastuzumab treatment compared to pre-treatment levels. Furthermore, miR-3529-3p was also downregulated in cells resistant to trastuzumab. Notably, overexpressing miR-3529-3p counteracted trastuzumab resistance. Additionally, miR-3529-3p mitigated chemoresistance by inhibiting the Wnt signaling pathway through positively regulating HOOK3 expression. In summary, miR-3529-3p in exosomes plays a crucial role in overcoming trastuzumab resistance, highlighting its potential as both a therapeutic target and a prognostic marker for individuals with breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsExosomesTrastuzumabBreast NeoplasmsAntineoplastic Agents, ImmunologicalHumansDrug Resistance, NeoplasmWnt Signaling PathwayFemaleCell Line, TumorGene Expression Regulation, NeoplasticErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

Breast cancerExosomesTrastuzumabWnt/β-catenin signalingmiR-3529-3p

Substanzen

MicroRNAsTrastuzumabAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province 150081, China.
  • Department of Stomatology, Beijing Shunyi District Hospital, Beijing 101300, China.
  • Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang Province 150081, China. Electronic address: 0566@hrbmu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhu, J., Lu, Y., & Zhang, Q. (2025). Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115160

Vancouver

Zhu J, Lu Y, Zhang Q. Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115160

BibTeX
@article{Zhu2025,
  author = {Zhu, Junwen and Lu, Ying and Zhang, Qingyuan},
  title = {Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115160}
}
Kostenlos starten →